Physician profile
Guy D Roberts
NPI 1528085156
$15,053.57
in general payments reported to CMS, 2019-2025
67 companies · $3,001 in 2025
The $3,001 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,379 · 2020: $376 · 2021: $808 · 2022: $2,434 · 2023: $3,192 · 2024: $2,864 · 2025: $3,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,968 · Education: $88.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,967.99 |
| Education | $88.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,030.66 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $1,094.73 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $679.57 | 2019-2025 | |
| Novo Nordisk INC | $628.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $536.59 | 2019-2025 | Rexulti, Nuedexta |
| Imbed Biosciences INC. | $528.00 | 2023 | |
| Allergan, INC. | $489.77 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.63 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $394.37 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Axsome Therapeutics, INC. | $363.16 | 2023-2025 | Auvelity, Sunosi |
| Amgen INC. | $356.91 | 2019-2025 | Repatha, Otezla, Repatha |
| Teva Pharmaceuticals USA, INC. | $327.68 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Astrazeneca Pharmaceuticals LP | $322.79 | 2019-2025 | Farxiga |
| Sumitomo Pharma America, INC. | $318.46 | 2023-2025 | Gemtesa, Aptiom |
| Sanofi-Aventis U.S. LLC | $307.94 | 2019-2025 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.